← Back to Search

Nurse Practitioner-Led Smoking Cessation Program for Smoking (STOP-NPT3 Trial)

Phase 2

Recruiting

Led By Quinn R Pack, MD

Research Sponsored by Baystate Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Admitted to Baystate Medical Center in Springfield, MA with a cardiac or pulmonary disease diagnosis will be eligible to participate in this trial

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 7 days after hospital discharge

Awards & highlights

STOP-NPT3 Trial Summary

This trial aims to improve smoking cessation treatment by utilizing the opportunity that hospitalization provides, with a team led by a nurse practitioner, and measuring the economic value.

Who is the study for?

This trial is for patients admitted to Baystate Medical Center in Springfield, MA with heart or lung diseases who smoke cigarettes. Participants must speak English and not be pregnant, nursing, planning hospice care, have a life expectancy under 6 months, current suicidal thoughts, or use daily smoked marijuana.Check my eligibility

What is being tested?

The study tests if a Nurse Practitioner-led Tobacco Treatment Team (NPT3) can improve smoking cessation over Enhanced Usual Care (EUC) in hospitalized smokers with cardiopulmonary disease. It measures the use of smoking cessation pharmacotherapy and checks for non-smoking status at 1 week and after 6 months using breath analysis.See study design

What are the potential side effects?

While specific side effects are not listed for this intervention focused on counseling and support services, any potential side effects would likely stem from the smoking cessation pharmacotherapy prescribed as part of the treatment.

STOP-NPT3 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am admitted to Baystate Medical Center with a heart or lung condition.

STOP-NPT3 Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 7 day point-prevalence: a. 7 days after hospital discharge b. 1 month after discharge c. 3 months after discharge

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~7 day point-prevalence: a. 7 days after hospital discharge b. 1 month after discharge c. 3 months after discharge

This trial's timeline: 3 weeks for screening, Varies for treatment, and 7 day point-prevalence: a. 7 days after hospital discharge b. 1 month after discharge c. 3 months after discharge for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Proportion of patients reporting smoking cessation abstinence (7 day point prevalence at 6 months)

Proportion of patients using guideline concordant smoking cessation medication at 7 days

Secondary outcome measures

Proportion of patients reporting continuous abstinence smoking cessation

Proportion of patients reporting smoking cessation abstinence (7 day point prevalence at 7 days, 30days, and 90 days post- discharge)

Proportion of patients using any smoking cessation medication throughout study time frame

+1 more

Other outcome measures

Cigarettes smoked per day

Longest period of continuous abstinence

Proportion of patients reporting E-cigarette use

+3 more

STOP-NPT3 Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Personalized Care: Nurse Practitioner led Tobacco Treatment Team (NPT3)Experimental Treatment1 Intervention

The investigators will administer the personalized care NPT3 intervention to randomized patients.

Group II: Enhanced usual care (EUC)Active Control1 Intervention

The investigators will administer the enhanced usual care intervention to randomized patients.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Baystate Medical CenterLead Sponsor

63 Previous Clinical Trials

43,849 Total Patients Enrolled

University of Massachusetts Chan Medical School, WorcesterUNKNOWN

University of Texas at AustinOTHER

353 Previous Clinical Trials

80,820 Total Patients Enrolled

Media Library

Nurse Practitioner Tobacco Treatment Team (NPT3) Clinical Trial Eligibility Overview. Trial Name: NCT05733767 — Phase 2

Smoking Cessation Research Study Groups: Enhanced usual care (EUC), Personalized Care: Nurse Practitioner led Tobacco Treatment Team (NPT3)

Nurse Practitioner Tobacco Treatment Team (NPT3) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05733767 — Phase 2

Smoking Cessation Clinical Trial 2023: Nurse Practitioner Tobacco Treatment Team (NPT3) Highlights & Side Effects. Trial Name: NCT05733767 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What risk factors should be considered when evaluating the effectiveness of a Personalized Care: Nurse Practitioner led Tobacco Treatment Team (NPT3)?

"The safety of the Personalized Care: Nurse Practitioner led Tobacco Treatment Team (NPT3) was assessed to be a 3, since it is already an approved Phase 4 trial."

Answered by AI

What is the sample size for this research project?

"Indeed. According to the data provided on clinicaltrials.gov, this medical trial is currently recruitmentg and was initially posted on November 3rd 2022. This study requires 424 patients from one location for completion."

Answered by AI

Are recruitment efforts currently underway for this clinical trial?

"Affirmative. Clinicaltrials.gov hosts information that verifies this clinical trial is still seeking candidates, having been initially posted on November 3rd 2022 and last updated on February 8th 2023. The research team intends to recruit 424 participants from a single site."

Answered by AI

What is the goal of this experiment?

"This clinical trial, which will be evaluated over a 7 day period post hospital discharge, aims to ascertain the percentage of patients who have achieved smoking cessation abstinence at 6 months. Secondary objectives include assessing the usage of any smoking cessation medication throughout the study, as well as ascertaining self-reported non-usage of tobacco products at 7 days, 30 days and 90 days post discharge - with an emphasis on continuous abstinence since hospital discharge."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study

2022. "Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05733767.

All > Smoking Cessation